Blog
RSS FeedPosted by Michael Wonder on 30 Nov 2020
Schedule of Pharmaceutical Benefits - 1 December 2020 update
1 December 2020 - The December 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Nov 2020
New Zealand Pharmaceutical Schedule - 1 December 2020
1 December 2020 - The December 2020 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Nov 2020
Forxiga approved in Japan for chronic heart failure
30 November 2020 - Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failure with reduced ejection ...
Posted by Michael Wonder on 30 Nov 2020
Dupixent (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
30 November 2020 - Pivotal trial showed more than four times as many children achieved itch reduction and more than three ...
Posted by Michael Wonder on 30 Nov 2020
GPs tell inquest they were unaware PHARMAC changed their patients' epilepsy drugs
30 November 2020 - Two GPs caring for patients who died after switching brands of an epilepsy drug say they were ...
Posted by Michael Wonder on 29 Nov 2020
Canada bans mass exports of prescription drugs
29 November 2020 - Canada has banned the export of some prescription medicines in order to prevent a shortage in ...
Posted by Michael Wonder on 29 Nov 2020
Key PBS listing to save Australians with severe back and neck pain more than 20,000 dollars
29 November 2020 - Thousands of Australians with debilitating back and joint pain will have access to a life changing treatment ...
Posted by Michael Wonder on 29 Nov 2020
PBS support for Australians living with leukaemia
28 November 2020 - Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded ...
Posted by Michael Wonder on 28 Nov 2020
Vertex announces European Commission approval for Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor) for eligible children with cystic fibrosis ages 6-11 years
27 November 2020 - The combination therapy is a new treatment option for CF patients who are homozygous for F508del. ...
Posted by Michael Wonder on 28 Nov 2020
Polaryx Therapeutics receives both rare paediatric disease and orphan drug designations for the treatment of GM2 gangliosidosis with PLX-300
25 November 2020 - Polaryx Therapeutics announced today that it has received from the U.S. FDA both rare paediatric disease and ...
Posted by Michael Wonder on 28 Nov 2020
FDA approves first treatment for weight management for people with certain rare genetic conditions
27 November 2020 - The U.S. FDA has approved Imcivree (setmelanotide) for chronic weight management (weight loss and weight maintenance for ...
Posted by Michael Wonder on 28 Nov 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases announce extension of PDUFA date for pegunigalsidase alfa for the proposed treatment of Fabry disease
27 November 2020 - Protalix BioTherapeutics today announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) ...
Posted by Michael Wonder on 27 Nov 2020
Dr Crawshaw takes over as PHARMAC’s medical director after COVID challenges in the UK
27 November 2020 - PHARMAC is pleased to announce that Dr Shirley Crawshaw, seven months after she was appointed, has arrived ...
Posted by Michael Wonder on 27 Nov 2020
Proposal for funded multiple sclerosis treatments
27 November 2020 - PHARMAC is proposing some changes to the way that multiple sclerosis treatments are funded, as well ...
Posted by Michael Wonder on 26 Nov 2020
TGA announces approval of new medicine from ASX listed company
26 November 2020 - Afamelanotide acetate (Scenesse) was approved on 22 October 2020. ...